A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.
Inclusion Criteria:
Exclusion Criteria:
Porto Alegre, 90610-000, Brazil
São Paulo, 01246 000, Brazil
Wuhan, 430030, China
Osaka Sayama Shi, 589 8511, Japan
Shiwa-gun, 028-3695, Japan
Toon-shi, 791-0295, Japan
Warsaw, 02-781, Poland
Kuzmolovsky, 188663, Russia
Gyeongsangnam-do, 52727, South Korea
Jeollanam-do, 58128, South Korea
Adana, 01250, Turkey (Türkiye)
Istanbul, 34098, Turkey (Türkiye)
Dnipro, 49102, Ukraine